A combination of immunotherapy drugs for people who have less advanced melanoma was evaluated by Heinzerling et al. They showed the efficiency of BRAF and MEK inhibitors (BRAFi + MEKi), combined, as an established therapeutic option in patients with BRAF-mutated advanced melanoma. Here, MAP2K7 is linked to melanoma.